You are here
Expertise: Bacterial Spore Germination, Bio-organic Chemistry, Bioterrorism, Enzymology
Ernesto Abel-Santos’ research combines the areas of organic chemistry, biochemistry and microbiology. In his lab, Abel-Santos works with bacterial spores, including anthrax and the hospital infection, Clostridium difficile (C-diff). He also is part of a collaborative research group looking at bacteria that affects chickens and honeybees.
Abel-Santos developed new techniques for evaluating mechanisms of Bacillus and Clostridium spore germination. He also investigates new methods to control anthrax infections, which are resistant to most antiseptic and antibiotic treatments. He has developed nucleoside inhibitors against anthrax spore germination.
He is the co-founder of Abel Therapeutics LLC, a start up company that is researching, developing, and commercializing the first and only preventative medicine for treating Clostridium difficile, one of the fastest growing epidemics in the U.S. C-diff spores can be contracted anytime a patient is in a hospital, nursing home, surgery center, or other similar facility.
- Ph.D., Bioorganic Chemistry, Washington School of Medicine, St. Louis, Missouri
- B.S., Chemistry, Universidad Autónoma de Santo Domingo, Dominican Republic
Articles Featuring Ernesto Abel-Santos
From finances to energy, health care, and more, UNLV graduate student researchers are asking important questions about America’s future.
UNLV has reached a licensing agreement with Abel Therapeutics, a start-up company that seeks to commercialize the discoveries of biochemistry professor Ernesto Abel-Santos.